This article is more than 5 years old. Information may no longer be current.

2018’s top five retina stories

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Retina news in 2018 included study results, an FDA approval and live coverage of the American Society of Retina Specialists and Euretina meetings.

Here are the top five most-read retina-related articles on Healio.com/OSN this year:

Hundreds of clinics in US offering stem cell therapies without FDA approval

A cross-sectional, clinical study of stem cell therapy clinics found 40 companies with 76 clinics across the United States offering patients non-FDA approved “cell therapy” for ocular conditions. Read more.

Study finds correlation between fish intake, diabetic retinopathy severity in Asian population

The study was conducted within the Singapore Diabetes Management Project and was aimed at evaluating the association of dietary fish intake with the severity of diabetic retinopathy in Asian individuals with type 2 diabetes living in Singapore. Read more.

Europe approves first gene therapy for retinal dystrophy

Luxturna will be authorized in all 28 EU member states as well as Norway, Iceland and Lichtenstein. Read more.

FDA approves Eylea 12-week dosing for wet AMD

The FDA has approved a supplemental biologics license application for a 12-week dosing schedule of Eylea injection in wet age-related macular degeneration patients. Read more.

Nightstar gene therapy used in first US patient with X-linked retinitis pigmentosa

A patient at Bascom Palmer Eye Institute has become the first in the United States to receive an innovative gene therapy treatment for X-linked retinitis pigmentosa as part of a Nightstar Therapeutics clinical trial. Read more.